COMET-1 study stays course, Exelixis falls on investor hopes
This article was originally published in Scrip
Executive Summary
Exelixis shares took a beating on 26 March based on an interim review of the Phase III COMET-1 clinical trial for Cometriq (cabozantinib) in the treatment of metastatic castrate-resistant prostate cancer (mCPRC), but not because the analysis revealed a specific safety or efficacy concern.